Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune dysfunction to disease in a subset of patients July 06, 2026 -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant schizophrenia. The Phase 2 study is an open-label trial designed to evaluate the e

First ever APRIL inhibitor to demonstrate statistically significant eGFR stabilization with evidence of improvement versus placebo over two years, highlighting VOYXACT's promising ability to provide long-term kidney protection and enhance clinical outcomes in IgAN VOYXACT showed robust reductions in risk of progression to kidney failure, reinforcing the therapeutic potential of selectively blocking APRIL VOYXACT® received U.S. FDA accelerated approval for reduction in proteinuria in adults wit

The FDA approved the expansion of Casgevy, which had previously been greenlit for patients 12 and up, into a younger pediatric population under the agency’s Commissioner’s National Priority Voucher program. The FDA has approved a pediatric expansion of Vertex Pharmaceuticals’ gene therapy Casgevy, allowing its use in children 2 years and up who have sickle cell disease and transfusion-dependent beta thalassemia. Casgevy is the first genetic medicine for these indications that can be used in yo

The Life Sciences category in PatSnap Open Platform MCP Servers Marketplace AI agents are changing how teams search, analyze, and act on information. But for life sciences teams, the real challenge is not only generating text — it is giving agents reliable access to specialized scientific, clinical, regulatory, and commercial intelligence. That is why PatSnap Open Platform is launching 12 Life Sciences MCP Servers: a new way for developers and innovation teams to connect life sciences intellig

Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Divarasib showed clinically meaningful improvements in progression-free survival compared to approved KRAS G12C inhibitors; no new safety signals were observed Statistical significance for overall survival was achieved at the interim analysis in this poor-prognosis patient population Data will be submitted to health authorities and presented at an upco

First gene replacement therapy in the EU for broad population with SMA, including children two years and older, teens and adults Fixed, one-time dose designed to replace the faulty SMN1 gene, providing a distinct option from ongoing dosing approaches Novartis gene replacement therapies now eligible in the EU for people with SMA across all age groups July 2, 2026 – Novartis today announced that the European Commission (EC) has approved Itvisma® (onasemnogene abeparvovec) for the treatment of chi

July 02, 2026 -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced results from two Phase 1/2 clinical trials evaluating zoldonrasib, its oral RAS(ON) G12D-selective covalent inhibitor, in combination regimens for patients with RAS G12D metastatic pancreatic ductal adenocarcinoma (PDAC). The results, which will be presented today in a proffered paper session at the 2026 European

Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Divarasib showed clinically meaningful improvements in progression-free survival compared to approved KRAS G12C inhibitors; no new safety signals were observed Statistical significance for overall survival was achieved at the interim analysis in this poor-prognosis patient population Data will be submitted to health authorities and presented at an upcomi

First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in China July 02, 2026 -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (NDA) for ORPATHYS® (savolitinib) has been granted conditional approval by the China National Medical Products Administration (“NMPA”) for the treatment of locally advanced or metastatic gastric cancer or gastroesophageal ju

July 1, 2026 -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in children aged 3 months to under 4 years with classic congenital adrenal hyperplasia (CAH). Crinecerfont, marketed as CRENESSITY®, is approved in the United States as an adjunctive treatment to glucocorticoid replacement to control androgens in adult and pediatric patients 4 years of age and older with classic CAH. "Infa